Abstract: In order to make available the health-promoting and healing properties of curcumin to the human or animal organism, also in combination with at least one further active substance, a solubilizate consists of or contains a content of curcumin equal to or smaller than 10 wt %, preferably equal to or smaller than 7.5 wt %, most preferably 6 wt %, and at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, namely polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, with an average diameter of the curcumin-loaded micelles ranging from 5 nm to 40 nm, preferably from 6 nm to 20 nm, most preferably from 7 nm to 10 nm, for use in particular as a dietary supplement and/or pharmaceutical drug for treating and/or preventing diseases involving inflammation, cancer and other diseases.

Abstract: In order to provide a formulation for xanthohumol which has an improved anti-inflammatory effect compared to native xanthohumol, the disclosure provides a solubilizate containing, in particular consisting of xanthohumol with a content of less than or equal to 35 wt. %, preferably less than or equal to 15 wt. %, most preferably 9 wt. % to 12 wt. %, and at least one emulsifier having an HLB value in a range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80.

Abstract: A solubilizate comprises curcumin in a content of less than or equal to 10 wt %, preferably less than or equal to 8 wt %, most preferably 3 wt % to 7 wt %, one or more boswellia acids and/or one or more boswellia acid derivatives in a total content of less than or equal to 10 wt %, preferably less than or equal to 8 wt %, most preferably 4.7 wt % to 6.6 wt %, xanthohumol in a content of less than or equal to 10 wt %, preferably less than or equal to 5 wt %, most preferably 1 wt % to 3 wt %, and at least one emulsifier with an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80.

Abstract: A solubilize composed of curcumin in a quantity of less than or equal to 10% by weight, preferable less than or equal to 7.5% by weight, particularly preferable 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin in between 5 nm and 40 nm, preferable between 6 nm and 20 nm, particularly preferable between 7 nm and 10 nm.

Abstract: A solubilizate comprises curcumin in a content of less than or equal to 10 wt %, preferably less than or equal to 8 wt %, most preferably 3 wt % to 7 wt %, one or more Boswellia acids and/or one or more Boswellia acid derivatives in a total content of less than or equal to 10 wt %, preferably less than or equal to 8 wt %, most preferably 4.7 wt % to 6.6 wt %, xanthohumol in a content of less than or equal to 10 wt %, preferably less than or equal to 5 wt %, most preferably 1 wt % to 3 wt %, and at least one emulsifier with an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80.

Abstract: In order to make available the health-promoting and healing properties of curcumin and/or cannabinoids to the human organism, the invention provides a solubilizate consisting of or comprising curcumin in a content equal to or less than 10 wt. %, and at least one cannabinoid as at least one further active substance, as well as at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids, and a solubilizate comprising, in particular consisting of at least one cannabinoid in a content of less than or equal to 10 wt. % and at least one emulsifier having an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids.

Abstract: In order to make available the health-promoting and healing properties of curcumin and/or the cannabinoid THC to the human organism, the invention provides a solubilizate consisting of or comprising curcumin in a content equal to or less than 10 wt. %, and at least THC as at least one further active substance, as well as at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids, and a solubilizate comprising, in particular consisting of at least one cannabinoid in a content of less than or equal to 10 wt. % and at least one emulsifier having an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids.

Abstract: In order to make available the health-promoting and healing properties of curcumin to the human or animal organism, also in combination with at least one further active substance, a solubilizate consists of or contains a content of curcumin equal to or smaller than 10 wt %, preferably equal to or smaller than 7.5 wt %, most preferably 6 wt %, and at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, namely polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, with an average diameter of the curcumin-loaded micelles ranging from 5 nm to 40 nm, preferably from 6 nm to 20 nm, most preferably from 7 nm to 10 nm, for use in particular as a dietary supplement and/or pharmaceutical drug for treating and/or preventing diseases involving inflammation, cancer and other diseases.

Abstract: In order to provide a formulation for xanthohumol which has an improved anti-inflammatory effect compared to native xanthohumol, the disclosure provides a solubilizate containing, in particular consisting of xanthohumol with a content of less than or equal to 35 wt. %, preferably less than or equal to 15 wt. %, most preferably 9 wt. % to 12 wt. %, and at least one emulsifier having an HLB value in a range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80.

Abstract: A solubilisate consisting of curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm.

Abstract: In order to make available the health-promoting and healing properties of curcumin to the human or animal organism, also in combination with at least one further active substance, a solubilizate consists of or contains a content of curcumin equal to or smaller than 10 wt %, preferably equal to or smaller than 7.5 wt %, most preferably 6 wt %, and at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, namely polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, with an average diameter of the curcumin-loaded micelles ranging from 5 nm to 40 nm, preferably from 6 nm to 20 nm, most preferably from 7 nm to 10 nm, for use in particular as a dietary supplement and/or pharmaceutical drug for treating and/or preventing diseases involving inflammation, cancer and other diseases.

Abstract: A solubilisation product consists of resveratrol, polysorbate 80 and polysorbate 20, at least one medium-chain triglyceride, and tocopherol. The solubilisation product is for use as a pharmaceutical product. The solubilisation product can be used as a pharmaceutical product in the treatment of Alzheimer's disease, Friedreich's ataxia, lysosomal diseases, in particular Tay-Sachs disease, cancer, diabetes, atherosclerosis, heart diseases, arthritis or autoimmune diseases.

Abstract: A solubilisation product consists of resveratrol, polysorbate 80 and polysorbate 20, and at least one medium-chain triglyceride.

Abstract: A solubilizate comprises curcumin in a content of less than or equal to 10 wt %, preferably less than or equal to 8 wt %, most preferably 3 wt % to 7 wt %, one or more boswellia acids and/or one or more boswellia acid derivatives in a total content of less than or equal to 10 wt %, preferably less than or equal to 8 wt %, most preferably 4.7 wt % to 6.6 wt %, xanthohumol in a content of less than or equal to 10 wt %, preferably less than or equal to 5 wt %, most preferably 1 wt % to 3 wt %, and at least one emulsifier with an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80.

Abstract: In order to make available the health-promoting and healing properties of curcumin to the human or animal organism, also in combination with at least one further active substance, a solubilizate consists of or contains a content of curcumin equal to or smaller than 10 wt %, preferably equal to or smaller than 7.5 wt %, most preferably 6 wt %, and at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, namely polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, with an average diameter of the curcumin-loaded micelles ranging from 5 nm to 40 nm, preferably from 6 nm to 20 nm, most preferably from 7 nm to 10 nm, for use in particular as a dietary supplement and/or pharmaceutical drug for treating and/or preventing diseases involving inflammation, cancer and other diseases.

Abstract: A solubilisation product consists of resveratrol, polysorbate 80 and polysorbate 20, at least one medium-chain triglyceride, and tocopherol. The solubilisation product is for use as a pharmaceutical product. The solubilisation product can be used as a pharmaceutical product in the treatment of Alzheimer's disease, Friedreich's ataxia, lysosomal diseases, in particular Tay-Sachs disease, cancer, diabetes, atherosclerosis, heart diseases, arthritis or autoimmune diseases.

Abstract: A solubilisation product consists of resveratrol, polysorbate 80 and polysorbate 20, and at least one medium-chain triglyceride.

Abstract: A solubilisate composed of curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm.

Abstract: A solubilisate composed of curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm.

Abstract: Described is a solubilizate of a preservative containing an aliphatic and/or aromatic acid such as sorbic acid and/or benzoic acid that is free of stabilizing agents, as well as one or more emulsifiers with an HLB value between 9 and 18 with a concentration of about 50% and about 95% emulsifier with regard to the total quantity of the solubilizate, and a procedure for the production of such a solubilizate.